Equities research analysts expect AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to report earnings per share (EPS) of ($0.58) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for AMAG Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.10) and the highest is ($0.08). AMAG Pharmaceuticals posted earnings of $0.07 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 928.6%. The company is expected to report its next earnings report on Tuesday, May 1st.
According to Zacks, analysts expect that AMAG Pharmaceuticals will report full year earnings of ($3.33) per share for the current financial year, with EPS estimates ranging from ($5.16) to ($1.82). For the next financial year, analysts anticipate that the company will report earnings of ($1.49) per share, with EPS estimates ranging from ($2.65) to ($0.22). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that follow AMAG Pharmaceuticals.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.68. The firm had revenue of $158.30 million during the quarter, compared to the consensus estimate of $158.84 million. AMAG Pharmaceuticals had a negative net margin of 8.93% and a negative return on equity of 7.13%. The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.31) earnings per share.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Palo Alto Investors LLC raised its holdings in shares of AMAG Pharmaceuticals by 1.5% in the fourth quarter. Palo Alto Investors LLC now owns 3,493,220 shares of the specialty pharmaceutical company’s stock valued at $46,285,000 after buying an additional 51,987 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of AMAG Pharmaceuticals by 25.1% in the fourth quarter. Renaissance Technologies LLC now owns 851,900 shares of the specialty pharmaceutical company’s stock valued at $11,288,000 after buying an additional 170,900 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its holdings in shares of AMAG Pharmaceuticals by 19.5% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 778,488 shares of the specialty pharmaceutical company’s stock valued at $10,316,000 after buying an additional 126,780 shares during the last quarter. Prudential Financial Inc. raised its holdings in shares of AMAG Pharmaceuticals by 35.7% in the third quarter. Prudential Financial Inc. now owns 725,357 shares of the specialty pharmaceutical company’s stock valued at $13,382,000 after buying an additional 190,660 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in shares of AMAG Pharmaceuticals by 14.2% in the third quarter. Russell Investments Group Ltd. now owns 645,182 shares of the specialty pharmaceutical company’s stock valued at $11,903,000 after buying an additional 80,217 shares during the last quarter.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) traded up $0.25 during mid-day trading on Monday, hitting $20.75. 301,995 shares of the company were exchanged, compared to its average volume of 1,332,237. The company has a current ratio of 1.74, a quick ratio of 1.60 and a debt-to-equity ratio of 0.93. The firm has a market capitalization of $705.64, a P/E ratio of -3.34 and a beta of 0.28. AMAG Pharmaceuticals has a 12-month low of $11.93 and a 12-month high of $24.85.
TRADEMARK VIOLATION NOTICE: “-$0.58 Earnings Per Share Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/03/12/0-58-earnings-per-share-expected-for-amag-pharmaceuticals-inc-amag-this-quarter.html.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.